

Introduction

Background

- Key biomarkers of Alzheimer's disease (AD) can be used to measure the progression of the illness within a particular patient.
- One particular area of interest has been the subtyping of such biomarkers or, in other words, identifying a threshold such that all patients who meet such threshold can be determined to be at high risk for the disease.
- Subtyping allows for early detection of AD and possible treatment intervention.

Objective

- We want to define subtypes for 16 key biomarker candidates of AD and examine whether proposed subtypes produce significant genetic (SNP) bases.




Figure 1. Divided groups of subjects after subtyping.

Materials

- Alzheimer's Disease Neuroimaging Initiative (ADNI) data: There were a total of 1576 participants and 565,373 SNPs assessed for significant associations.
- Biomarker candidates: AV45, FDG, PTAU, TAU, ABETA, CDRSB, ADAS13, MMSE, RAVLT.learning, FAQ, Ventricles, Hippocampus, WholeBrain, Entorhinal, Fusiform, and MidTemp
- Covariates: Patient age, gender, education, and subtype group (0, 1, or -9) were used.

Age	Sex (Male/Female)	Education(Year)
73.87 ± 7.28	889/687	15.85 ± 2.87

Figure 2. Participants' demographic information

GWAS analysis:

- We used a p-value significance threshold of 5×10^{-8} to determine whether a significant SNP association existed after running PLINK.

Methodology

Step 1 Step 2 Step 2(a) Step 3

Histogram analysis of CN (Cognitively normal), EMCI (Early mild cognitive impairment), LMCI (Late mild cognitive impairment), and AD data

Genome-wide association studies (GWAS) analysis on subtyped data comparing CN to EMCI+LMCI+AD patients within defined subtype

If GWAS returns no significant SNP associations, return to Step 1 and select new threshold.

Statistical analysis (pairwise t-test)

Results

- Various thresholds were assessed as possible subtype thresholds for each biomarker.
- For each biomarker, subjects were split into the three groups and GWAS analysis was used to determine whether each subtype yielded significant genetic (SNP) associations.
- We used one subtype to define other biomarkers and created violin plots of all 16 biomarkers and their controls.
- A pairwise t-test was performed between each biomarker's subtype and control to determine whether the subtype used to define the groups produced significant groupings in other biomarkers.

Histogram Results




Figure 3. Example histograms for AV45




Figure 4. Example histograms for FDG

AV45	FDG	PTAU	TAU	ABETA	CDRSB	ADAS13	MMSE	RAVLT.learning	FAQ	Ventricles	Hippocampus	WholeBrain	Entorhinal	Fusiform	MidTemp
L	S	L	L	S	L	L	S	S	L	L	S	S	S	S	S

Figure 5. Directionality results (L: larger values signify AD progression, S: smaller values signify AD progression)

GWAS Results




Figure 6. Heatmap displays associations between biomarkers and SNPs received from PLINK analysis. Red X's represent the most significant associations. X-axis represents SNPs; y-axis represents biomarkers

AV45	FDG	PTAU	TAU	ABETA	CDRSB	ADAS13	MMSE	RAVLT.learning	FAQ	Ventricles	Hippocampus	WholeBrain	Entorhinal	Fusiform	MidTemp
>1.4	<1.1	>50	>500	<850	>9	>40	<27	<5	>15	>80000	<6000	<1000000	<3000	<16000	<18000

Figure 7. Subtyping results of all biomarkers

Results (cont.)

Pairwise T-test Results





Figure 8. Violin plots with normalized data of all biomarkers

Figure 9. Enlarged violin plot for TAU



FDG Significant P-Values

- Hippocampus: 0
- MidTemp: 0
- WholeBrain: 1.07×10^{-294}

ABETA Significant P-Values

- Hippocampus: 0
- Fusiform: 0
- MidTemp: 0
- WholeBrain: 0

RAVLT.learning Significant P-Values

- Fusiform: 0
- MidTemp: 0
- WholeBrain: 3.36×10^{-305}

Figure 10. Most significant t-test results for possible associations between various biomarkers

Conclusion

- Out of the 16 biomarker candidates subtyped and assessed, we determined that the threshold of 15 for FAQ yielded the most significant genetic associations and could be further explored as a possible indication of AD.
- Our findings also indicate that a few biomarkers could possibly be associated with others and used to indicate the development of AD, such as that between FDG and MidTemp or ABETA and WholeBrain.
- Having focused on GWAS and biomarker evaluation in this project, in the future, we could move to analyze survival outcome as well.
- We could also use other data to back our findings in this study and use other strategies such as ones involving machine learning to subtype patients.

Acknowledgements

- Supported by the Shen Lab at the Perelman School of Medicine at the University of Pennsylvania and the Penn Undergraduate Research Mentoring (PURM) program.
- Full ADNI Acknowledgement is available at: https://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf.